secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2023-01-30T23:59:59+00:00
Accession:  0001193125-23-018465
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx closes collaboration with Kite/Gilead for CART-ddBCMA; sells $100M of stock to Gilead
--------------------------------------------------------------------------------

- Global collaboration to co-develop and co-commercialize CART-ddBCMA for relapsed/refractory multiple myeloma.
- CART-ddBCMA is in Phase 2 pivotal trial; companies will co-commercialize in U.S., Kite outside U.S.
- Arcellx sold 3,478,261 shares of common stock to Gilead for aggregate ~$100M.
- Closing followed expiration of HSR waiting period; deal previously disclosed in December 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312523018465/0001193125-23-018465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312523018465/d434551d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-018465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer